...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Thoughts on ZCC

Toinv, yes Sanjay Lakhotia came to Zenith with Julie Cherington. He had worked for her at Pathway where she was CEO. I have noticed that she has been appointed to the BoD's of a few biotechs in the recent past. Can't say the same for Don, probably speaks to relative quality of business talent. 

Share
New Message
Please login to post a reply